iC9 CAR CSPG4 T-cell therapy- Bellicum Pharmaceuticals
Alternative Names: iC9-CAR-CSPG4 T cells - Bellicum Pharmaceuticals; iC9.CAR-CSPG4 T cells - Bellicum PharmaceuticalsLatest Information Update: 04 Dec 2024
Price :
$50 *
At a glance
- Originator Bellicum Pharmaceuticals
- Developer Bellicum Pharmaceuticals; UNC Lineberger Comprehensive Cancer Center
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Squamous cell cancer